ARF related protein 1Genealiases: ARL18 · ARP · Arp1
Q-omics provides the consensus-scored ARFRP1 profile across patient tissues and cancer cell-line models. ARFRP1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ARFRP1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ARFRP1 protein abundance shows 18,885 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where ARFRP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARFRP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARFRP1 survival associations across molecular data types. ARFRP1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARFRP1 RNA expression–survival associations across cancer types. High ARFRP1 expression shows unfavorable associations in LIHC, KIRC, LGG and KICH, but favorable associations in READ and THYM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ARFRP1 RNA expression.
This table summarizes ARFRP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARFRP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARFRP1 shows lower tumor expression in UCEC and higher tumor expression in HNSC, COAD, KIRC, LIHC and STAD. The HNSC box plot shows higher ARFRP1 RNA expression in tumor versus normal tissue (log2 FC = +1.171, t-test p < 0.001).
This table shows molecular features associated with ARFRP1 in patient tissues and cancer cell lines. In patient samples, ARFRP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARFRP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
